Member Announcements 2007

 

November 28, 2007

Application to Present Deadline for Invest Northwestâ„¢ 2008 is Dec. 7, 2007

 

November 27, 2007

Despite record spending, returns on R&D investment plummet. It is time to take action.

 

November 27, 2007

Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team

 

November 26, 2007

Medical Ventures completes U.S. FDA application for Metricath Gemini

 

November 22, 2007

Dr. Robert N. Young Receives First Genome British Columbia Research Leadership Award

 

November 20, 2007

BioPartnering North America Continues to Attract the Strong Support of Canada’s Leading Life Science Associations

 

November 19, 2007

Inaugural Director Appointed for Innovative New Institute at St. Paul’s Hospital

 

November 14, 2007

CANTEST’S Chariman of the Board Honoured as Business Person of the Year at Burnaby Business Excellence Awards

 

November 14, 2007

Forbes Medi-Tech Announces Third Quarter 2007 Financial Results – ~Company Reports 33% Increase in Revenues Over Previous Year~

 

November 13, 2007

Forbes Medi-Tech Announces Timing of Third Quarter Financials and Corporate Update

 

November 7, 2007

Medical Ventures’ Metricath Gemini influenced stent selection, course of treatment in GAAME trial – Physician feedback results indicate clinical utility

 

November 7, 2007

Medical Ventures reports Q3 2007 results

 

November 1, 2007

Amgen Canada Releases Criteria for BC Science Teacher’s Awards

 

November 1, 2007

Neuromed Initiates Pivotal Phase 3 Clinical Trial of NMED-1077 for Chronic Pain

 

November 1, 2007

Diversified Bio-Medics, Inc. (DBMI), with a Focus on the Development of cGMP Facilities for Bio-Manufacturing, Announces the Open Search for Qualified Candidates for the Positions of President and Chief of Operations

 

October 31, 2007

Zymeworks Inc. announces collaborative research agreements for computational antibody modeling and the development of tuberculosis therapeutic agents

 

October 30, 2007

Forbes Medi-Tech Enters Final Steps in Compound Selection for Asthma and Type 2 Diabetes

 

October 26, 2007

Sorin Group: Announces U.S. FDA’s Approval to Market its Mitroflow Aortic Pericardial Heart Valve in the United States

 

October 24, 2007

Forbes Medi-Tech Increases Revenue Guidance Range 16% to $8.75 to $9.25 Million

 

October 18, 2007

BioPartnering Europe (BPE) retains its reputation as the leading Biotech event in Europe as it entered its 15th anniversary year

LONDON, 18 October 2007 – Technology Vision Group LLC takes great pleasure in announcing the continued success of BioPartnering Europe (BPE), the longest continuously held European partnering event focused on the life sciences. Now in its 15th year, BPE took place at the QE II Conference Centre in Westminster, London, and was well attended by a large international audience of nearly 1300 senior executives representing all facets of the life sciences.

 

October 18, 2007

Pfizer Investment in British Columbia Healthcare Marks a New Era of Partnership

October 18th, 2007, VANCOUVER BC — Tuesday’s announcement by Pfizer Canada that they will be investing $4.25 million into two BC research initiatives (Significant Investments in British Columbia Healthcare Set the Province at the Forefront of Research in HIV/AIDS and Cardiovascular Prevention; Vancouver – Oct. 16, 2007) is seen by LifeSciences BC as a tremendous step forward in enhancing the role of international industry in advancing towards a sustainable healthcare system in British Columbia.

 

October 16, 2007

Integrative Consulting Services Signs Distribution Agreement with MarketResearch.com

Vancouver, Canada, October 16, 2007 – Integrative Consulting Services is pleased to announce that it is has signed a distribution deal with MarketResearch.com. Through the terms of the agreement, MarketResearch.com will sell market analyses of the clinical-development outsourcing industry published by Integrative Consulting Services.

 

October 16, 2007

Significant Investments In British Columbia Healthcare Set The Province At The Forefont Of Research In HIV/AIDS And Cardiovascular Prevention

Vancouver, BC- Oct 16,2007- Pfizer Canada is announcing today two significant healthcare research investments in British Columbia totaling $4.25 million. The first is an investment at the internationally renowned British Columbia Centre for Excellence in HIV/AIDS and the second is at St. Paul’s Hospital Foundation and Simon Fraser University to establish the first Canadian research chair in cardiovascular prevention.

 

October 16, 2007

Merck & Co., Inc. Licenses Snalp Technology From Protiva

Vancouver, BC, October 16th, 2007 – Protiva Biotherapeutics Inc. today reported that it has granted Merck & Co., Inc. a non-exclusive license to Protiva’s SNALP (Stable Nucleic Acid-Lipid Particles) technology for ongoing research and development of therapeutics in the emerging field of RNA interference (RNAi).

 

October 15, 2007

Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077

 

October 9, 2007

Maturation of the contract research market poses challenges to senior managers of contract research organizations

Vancouver, Canada, October 9, 2007 – Contract research is a multi-billion dollar industry and continues to grow at a double-digit rate. However, the growth in certain segments, notably clinical research and site management, is decelerating. This is suggestive of a market nearing maturation, which has important implications for managers of contract research organizations (CROs) according to Ahead of the Curve: Trends, Predictions and Survival Guide for the North American Contract Research Industry, a new report published by Integrative Consulting Services.

 

October 9, 2007

Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

CARLSBAD, Calif., Oct 09, 2007– Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that it has received a $1.25 million milestone payment in the form of equity securities in iCo Therapeutics. The milestone was related to the initiation of Phase 1 clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the treatment of various eye diseases, including diabetic macular edema.

 

October 9, 2007

More high school students to benefit from national science competition

OTTAWA, Oct. 9, 2007- BioTalent Canada, a national sponsor of the SABC program, is pleased to announce the Government of Canada’s funding renewal of the program and the launch of the 2007-08 challenge. “We are veryexcited about this,” says Colette Rivet, Executive Director of BioTalentCanada. “We will be able to reach more students, build on past programsuccesses, and have all regional winners come to Ottawa for a face-to-face national competition in the Spring.”

 

October 5, 2007

Neuromed President & CEO Dr. Christopher Gallen Named Finalist for Scrip Award’s “Executive of the Year”

CONSHOHOCKEN, PA and VANCOUVER, BC – October 5, 2007 – Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, is pleased to announce its President & CEO, Dr. Christopher Gallen, has been named a finalist for a 2007 Scrip Award in the category of “Executive of the Year.”

 

October 5, 2007

Neuromed President & CEO Dr. Christopher Gallen Named Finalist for Scrip Award’s “Executive of the Year”

 

October 4, 2007

Medical Ventures submits second PMA module to FDA Company seeking U.S. approval of Metricath Gemini device

 

October 2, 2007

Netherlands’s Largest SuperMarket Chain, Albert Heijn, Expands Range of Reducolâ„¢ Products ~Innovative Product Development Yields New Product in Organic Milk Category~

Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the Netherlands’s largest retailer, Albert Heijn, has launched an organic, cholesterol-lowering, skim milk drink incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducolâ„¢.

 

October 1, 2007

Phase I Data For the Twinstrand Drug TST10088 To Be Presented at International Cancer Therapeutics Conference

BURNABY, BC, Canada, October 1, 2007 – Twinstrand Therapeutics Inc. today announced that an abstract entitled, “Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors”, has been accepted for presentation at the Molecular Targets and Cancer Therapeutics International Conference to be held in San Francisco, California on October 22-26, 2007.

 

October 1, 2007

Medical Ventures announces change in executive management Alexei Marko assumes role of company president

 

September 27, 2007

Merck’s GARDASIL and JANUVIA Receive Prix Galien USA Top HonorsMerck’s GARDASIL and JANUVIA Receive Prix Galien USA Top Honors

Sept 27, 2007-GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine), Merck’s vaccine for the prevention of cervical cancer, received the Prix Galien USA 2007 Award for Best Biotechnology product, Merck & Co., Inc. announced today. In addition, JANUVIA(TM) (sitagliptin), the Company’s treatment of type 2 diabetes, received the 2007 Award for Best Pharmaceutical Agent. Both were presented at a ceremony in New York City on Sept. 25.

 

September 25, 2007

Twinstrand Therapeutics Files IND Application For Immuogen in Ricin Antidote Study

BURNABY, BC, Canada, September 25, 2007 – Twinstrand Therapeutics Inc. today announced that it has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the immunization of humans with a benign ricin-like toxoid.

 

September 21, 2007

LifeSciences British Columbia in partnership with BIOTECanada, presents: Championing Biotechnology Discovery and Invention with Dr. Roberta Bondar

VANCOUVER, Sept. 21 , 2007- On Wednesday September 26, LifeSciences BC is extremely proud to welcome Dr. Bondar to British Columbia for National Biotechnology Week celebrations, in her role as the National Champion for Biotechnology as selected by BIOTECanada.

 

September 21, 2007

PBR Laboratories Inc. Granted Establishment Licence for GMP testing by Health Canada

PBR Laboratories announced today it has received an Establishment Licence from Health Canada for testing pharmaceutical and nutraceutical products under Good Manufacturing Practice (GMP) guidelines.

 

September 17, 2007

Fulcrum Regulatory Services opens office in Vancouver

Fulcrum Pharma, the drug development and strategic outsourcing services company, is pleased to announce that it now has regulatory expertise based in a new office, located on the East side of Vancouver in British Columbia.

 

September 17, 2007

Twinstrand Therapeutics Granted NIAID Award for Monoclonal and Polyclonal Antibody Therapies to Treat Ricin Poisoning

BURNABY, BC, Canada, September 17, 2007 – Twinstrand Therapeutics Inc. announced today that it has been granted a US$1.5M award from the US National Institute of Allergy and Infectious Disease for research and development of antidotes to ricin poisoning.

 

September 17, 2007

Metricath used in live case at cardiovascular conference Doctors observe device in use during C3 teaching case

 

September 12, 2007

2007 BC Innovation Council Award Winners: British Columbia’s Innovation Forerunners Recognized for Outstanding Achievements

Vancouver, BC-September 12,  2007  – Mr. Hector MacKay-Dunn, QC, Chair of BC Innovation Council, is pleased to announce five outstanding British Columbians as winners of the 2007 BC Innovation Council Awards.

 

September 10, 2007

Northern Lipids Inc. (NLI) Builds Clinical Manufacturing Facility

Northern Lipids Inc. (NLI) is pleased to announce that it has completed the renovation and build-out of its’ new Burnaby facility. Located only minutes from Vancouver airport, just off Boundary Road in South Burnaby, the building is designed to support preclinical development of pharmaceutical products, and houses a facility that is suitable for the manufacture of sterile drug products for clinical trials.

 

September 10, 2007

Pilot study suggests Metricath is effective in renal artery procedures

September 10, 2007 – Richmond, BC – MEDICAL VENTURES CORP. (TSXV: MEV) announces that its Metricath Libra ® arterial and in-stent measurement system was shown in a pilot study to be effective for use in renal arteries, according to results shared at the New Cardiovascular Horizons (NCVH) conference in New Orleans.

 

September 10, 2007

Periowave(TM) Gum Disease Therapy: Positive Results From Meta-analysis

VANCOUVER, BC-Sept. 10, 2007- Ondine Biopharma Corporation (TSX: OBP; AIM:OBP), a medical technology company, today announced results of a meta-analysis (statistical review of pooled clinical trial data) of its Periowave(TM) Photodynamic Disinfection System in the treatment of gum disease. The

 

September 7, 2007

Welichem Biotech Successfully Moves to Higher Dose for Phase I Clinical Trials

BURNABY, BC, Aug. 7, 2007  – Welichem Biotech Inc. (“WBI” or the “Company”) (TSX-V: WBI – News) is very pleased to announce that the Phase I Clinical Trial of Welichem Biotech’s anti-psoriasis drug candidate is underway in Montreal, Quebec. The Clinical Trial is being run by Innovaderm Research Inc., which is responsible for the strict protocols, data gathering, and patient monitoring necessary to comply with applicable standards and procedures. Innovaderm has been active in medical research since 1999 and has an excellent reputation for the quality and standards of its research and the care it offers to subject patients. Innovaderm has a professional staff of doctors, certified Clinical Research Coordinators, and others within its staff of more than 40.

 

September 6, 2007

Fennobon of Finland Launches Cholesterol-Lowering Chewing Gum with Reducolâ„¢

Vancouver, Canada- September 7, 2007- Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announces Fennobon of Finland has launched the first cholesterol-lowering XyliDent Pro chewing gum incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducolâ„¢. Consumers in Finland will be able to purchase the gum in major retail chains across Finland.

 

September 5, 2007

GenoLogics’ Geneus Achieves GeneChip-compatibleâ„¢ Status with the Affymetrix GeneChip ® Microarray Platform

Victoria, BC, Canada ─ September 5, 2007 ─ GenoLogics, a leading developer of lab and data management software solutions for life sciences research, announced today the Company has joined the Affymetrix GeneChip-compatibleâ„¢ Applications Program, and its Geneus product has achieved GeneChip-compatibleâ„¢ status with the Affymetrix, Inc. (Nasdaq: AFFX) GeneChip ® microarray platform. GenoLogics has seamlessly integrated its Geneus solution, built for multiple genomics applications, with the Affymetrix GeneChip ® platforms, GeneChip Operating Software (GCOS) and the new GeneChip ® Command Consoleâ„¢ Software (AGCC).

 

September 5, 2007

U.S. cardiovascular conference to include Metricath Libra research

September 5, 2007 – Richmond, BC – MEDICAL VENTURES CORP. (TSXV: MEV) announces that its Metricath Libra ® arterial and in-stent measurement system will be featured in an emerging technology research presentation at the New Cardiovascular Horizons (NCVH) conference, taking place September 5-8 in New Orleans.

 

August 30, 2007

Cardiome and Astellas Announce Regulatory Extension

Vancouver, Canada and Deerfield, Illinois, USA, August 30, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has requested that Astellas and Cardiome participate in a panel review to be conducted by the Cardiovascular and Renal Drugs Advisory Committee on December 11-12, 2007. The New Drug Application (NDA) for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, will be reviewed as part of a two-day meeting regarding therapies for acute conversion of heart arrhythmias.

 

August 21, 2007

Allon named “Top 10” partnering candidate by expert conference

VANCOUVER, BC- August 21, 2007— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it’s Alzheimer’s program has been selected as one of the top 10 not yet partnered biotech programs in the world and the company will present at the prestigious Windhover Therapeutics Area Partnership conference. The conference is the industry’s most targeted partnering meeting, and is scheduled to take place October 24th to 26th, 2007 at the Loews Hotel, in Philadelphia, Pennsylvania. Presentations at the conference are by invitation only.

 

August 21, 2007

Protox acquires research program from Medicenna

VANCOUVER, BC-Aug. 21, 2007  – Protox Therapeutics Inc. (TSX-V:PRX) announced today that it has entered into an asset purchase agreement with Medicenna Ventures Inc. (“Medicenna”) for the acquisition of Medicenna’s HUMxin(TM) Program, a research program to develop fully humanized fusion proteins based upon the Bcl-2 family, which are key components of programmed cell death (“apoptosis”).

 

August 21, 2007

Neuromed Raises US$53.3 Million in Series E Financing to Accelerate Development of Pain Treatments

 

August 20, 2007

Ondine Announces Appointment of Dr. Timothy Rose as the Chairman of its Clinical Advisory Board

VANCOUVER, BC-  Aug. 20, 2007- Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company focused on photodisinfection technology, announces that Dr. Timothy Rose, DDS has accepted the position as chairman of its Clinical Advisory Board (CAB). Dr. Rose is a former president of both the American Academy of Periodontology and the American Dental Association. In addition to practising Periodontology in Wisconsin, Dr. Rose also holds positions on various boards and committees. Over the course of his career, Dr. Rose has received numerous prestigious awards in recognition of his contributions to dentistry.

 

August 17, 2007

Ondine Biopharma Announces Compliance with AIM Rule 26

VANCOUVER, BC, Aug 17, 2007 – Ondine Biopharma Corporation (“the Company”, TSX: OBP; AIM: OBP), a medical technology company, announces that the information required to be disclosed in accordance with Rule 26 of the AIM Rules for Companies is available in the “Shareholder Info” section of the Company’s website, www.ondinebiopharma.com/shareholder-info/, which is found under the heading “Investors” on the Company’s home page, www.ondinebiopharma.com.

 

August 15, 2007

Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

VANCOUVER, BC- Aug. 15 , 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing additional diameters of its Quill(TM) Self-Retaining System (SRS) Polydioxanone (PDO) product line.

 

August 15, 2007

Stem cell subtypes discovered by BC Cancer Agency

In a landmark study, researchers at the BC Cancer Agency have discovered that all blood stem cells are not created equal. The discovery adds another layer of understanding about the basic biology of blood stem cells, which may lead to improved treatments for leukemia patients.

 

August 14, 2007

Forbes Medi-Tech Reports Financial Results for the Quarter ended June 30, 2007 ~Steady growth in Reducolâ„¢ Sales Drives Increase in Revenues Over Previous Year~

Vancouver, Canada – Aug 14, 2007- Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the three and six-month periods ended June 30, 2007. Comparative periods for these statements are the three months and six month periods ended June 30, 2006, respectively. All amounts are in Canadian Dollars unless otherwise noted.

 

August 13, 2007

Angiotech announces expansion of innovative Quill(TM) SRS product line with new choice of absorbable sutures

VANCOUVER, BC- Aug. 13, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing a new polymer line of absorbable sutures, further broadening the offering of the Quill(TM) Self-Retaining System (SRS) product line.

 

August 8, 2007

Neuromed Announces that Merck & Co., Inc. Discontinues Development of Pain Drug Candidate, Joint Research Program Continues

CONSHOHOCKEN, PA and VANCOUVER, Aug. 8, 2007  – Neuromed Pharmaceuticalsannounced today that Merck & Co., Inc. and Neuromed have decided todiscontinue development of NMED-160 (also known as MK-6721), a Phase 2compound for the treatment of chronic pain.

 

August 7, 2007

Allon and TURNS expand collaboration for Phase II schizophrenia trial

VANCOUVER, BC- August 7, 2007  â€” Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in Schizophrenia and Affective Disorders (NARSAD) they will add an imaging-biomarker component to the current Phase II efficacy trial evaluating AL-108 as a treatment for schizophrenia-related cognitive impairment.

 

August 7, 2007

Phase I Clinical Trial Underway for Welichem Biotech

BURNABY, BC, Aug. 7, 2007- Welichem Biotech Inc. (“WBI” or the”Company”) (TSX-V: WBI) is very pleased to announce that the Phase I ClinicalTrial of Welichem Biotech’s anti-psoriasis drug candidate is underway inMontreal, Quebec.

 

August 7, 2007

Taiwan’s Largest Drink Producer Launches Reducolâ„¢-Based Milk Drink

Vancouver, Canada, Aug 8, 2007-  Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announces Uni-President Enterprises Corporation (UPEC), the largest non-alcoholic drinks producer in Taiwan, has launched a cholesterol-lowering milk drink incorporating Reducolâ„¢. The milk drink is marketed under the UPEC brand.

 

August 7, 2007

New National Association Represents Canada’s Research & Technology Parks

Vancouver, BC, August 7, 2007-The creation of the Canadian Association of University Research Parks / Association Canadienne des Parcs de Recherches d’Universite (AURP Canada) was announced. AURP Canada, which will represent 25 Canadian science, technology and research parks, will be a chapter of the Association of University Research Parks (AURP), which has offices in Washington, D.C. and Tucson, Arizona.

 

August 2, 2007

Angiotech appoints Laura Brege to its Board of Directors

VANCOUVER, Aug. 2, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that Laura Brege has been appointed to its Board of Directors.

 

August 2, 2007

Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint

August 7, 2007- Genzyme Corp. (Nasdaq: GENZ) today announced that its second phase 3 trial of MozobilTM (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similar to those reported two weeks ago in non-Hodgkin’s lymphoma.

 

August 1, 2007

OncoGenex Initiates Phase I Clinical Trial of OGX-427 in Cancer

VANCOUVER, Aug. 1, 2007  – OncoGenex Technologies Inc. today announced enrollment of the first patient in an open label, dose-escalation, multi-center Phase I clinical study evaluating a new investigational drug, OGX-427, in patients with breast, ovarian, bladder, prostate or lung cancer.

 

August 1, 2007

Association of University Research Parks: New National Association Represents Canada’s Research & Technology Parks

VICTORIA, BRITISH COLUMBIA- Aug. 1, 2007-  The creation of the Canadian Association of University Research Parks / Association Canadienne des Parcs de Recherches d’Universite (AURP Canada) was announced today. AURP Canada, which will represent 25 Canadian science, technology and research parks, will be a chapter of the Association of University Research Parks (AURP), which has offices in Washington, D.C. and Tucson, Arizona.

 

July 31, 2007

OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans

VANCOUVER and CARLSBAD, CA, July 31, 2007- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced encouraging preliminary data from an ongoing Phase II clinical trial of OGX-011 in combination with second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC).

 

July 30, 2007

Med BioGene Inc.: Dr. Nathan Yoganathan, President and Chief Scientific Officer, Transitions to Senior Advisory Role; Dr. Bradley Mclean Appointed Chief Scientific Officer

VANCOUVER, BRITISH COLUMBIA, July 30, 2007 – Med BioGene Inc. (TSX VENTURE:MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from cancer and cardiovascular disease, today announced that Dr. Nathan Yoganathan, MBI’s founder, President and Chief Scientific Officer has transitioned to a senior advisory role as Chief Scientific Advisor. Dr. Bradley McLean, a senior scientist with MBI, was appointed Chief Scientific Officer.

 

July 30, 2007

MIGENIX Partner Cadence Pharmaceuticals Gets FDA Agreement on Enrollment in Phase III Clinical Trial of Omigard(TM) for Preventing Catheter-Related Infections

VANCOUVER and SAN DIEGO, July 30, 2007-  MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, reports that the Company’s North American and European development and commercialization partner for Omigard(TM), Cadence Pharmaceuticals, has reached agreement with the U.S. Food and Drug Administration (FDA) to increase the number of patients to be enrolled in the ongoing Phase III clinical trial from 1,250 to 1,850.

 

July 25, 2007

Aspreva announces restructuring designed to drive long-term growth

VICTORIA, BC, July 25, 2007- Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV – News; TSX: ASV – News) today announced a reorganization of the company’s operations in order to better focus on core activities that are expected to drive long-term growth. To achieve this goal, the company expects to reduce staffing levels by approximately 25 percent, or 33 positions worldwide. As part of the restructuring, Dr. Richard Jones, Chief Scientific Officer, will be leaving the company. His responsibilities will be assumed by Dr. Usman Azam, Aspreva’s Chief Medical Officer.

 

July 19, 2007

Forbes Medi-Tech on Track for Corporate Objectives Including Revenue Growth

Vancouver,  British Columbia, July 19, 2007-  Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI), announces that its corporate objectives remain on track for year-over-year revenue growth while maintaining its commitment to change and improving Forbes’ profile through M&A activity.

 

July 19, 2007

Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint

Genzyme Corp. (Nasdaq: GENZ) today announced that it has successfully completed its phase 3 trial of MozobilTM(plerixafor) in non-Hodgkin’s lymphoma (NHL), and that the trial has robustly met its primary and secondary endpoints.

 

July 17, 2007

Protox Announces Manufacturing Agreement With Dompe For prx321

Vancouver, British Columbia, July 17, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) announced today that it has entered into an agreement with Dompepha.r.ma S.p.A. (Dompe) for clinical manufacture and commercial supply of PRX321, its lead product candidate in development for the treatment of primary brain cancer.

 

July 17, 2007

Medical Ventures completes minimum enrolment for GAAME clinical trial

July 17, 2007 – Richmond, BC – MEDICAL VENTURES CORP. (TSXV: MEV) announces the U.S. Food & Drug Administration has agreed to accept patient data from the GAAME clinical trial for the Metricath Gemini based on a revised statistical analysis plan that reduces the study’s minimum sample population to 107.

 

July 16, 2007

Nasdaq Approves Forbes Medi-Tech Transfer to Nasdaq Capital Market

Vancouver, BC, Canada -July 16, 2007- Forbes Medi-Tech Inc.’s (TSX:FMI and NASDAQ:FMTI) application has been approved to transfer its listing from the Nasdaq Global market to the Nasdaq Capital Market effective the opening of business July 23, 2007. The Nasdaq trading symbol for the Company’s common stock, “FMTI,” will not change.

 

July 16, 2007

Welichem Appoints Business Development Manager

BURNABY, BC, July 16, 2007 – Welichem Biotech Inc. (“WBI” or the “Company”) (TSX-V: WBI – News) is delighted to announce the appointment of Dr. Yan Chen as Business Development Manager.

 

July 12, 2007

Biotech research at BCIT gets funding boost

BURNABY, BC- July 12, 2007: Researchers at the British Columbia Institute of Technology (BCIT) recently received grant monies from the Canada Foundation for Innovation (CFI) to look into the effectiveness and safety of natural health products.

 

July 11, 2007

  1. William Freytag, PH.D. appointed Chairman and Chief Executive Officer of Aspreva Pharmaceuticals

Victoria,  BC – July 11, 2007- Aspreva Pharmaceuticals Corporation(NASDAQ: ASPV; TSX: ASV) today announced the appointment of Dr. J. William Freytag, 55, as Chairman and Chief Executive Officer, succeeding RichardGlickman, effective immediately. Mr. Glickman, one of Aspreva’s founders andthe company’s first Chairman and CEO, had announced in May 2007 his planneddeparture from Aspreva.

 

July 10, 2007

Welichem Gets Approval for Phase I Clinical Trials

BURNABY, BC, July 10, 2007- Welichem Biotech Inc. (“WBI” or the “Company”) (TSX-V: WBI) is proud to announce that on July 6, 2007, Health Canada approved the Company’s Clinical Trials Application (CTA) to begin WBI’s Phase I Clinical Trials of its anti-psoriasis drug candidate, WBI-1001.

 

July 10, 2007

Protox Announces positive clinical data from prostate cancer study

Vancouver, British Columbia, July 10, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) today announced positive top-line results from its Phase 1 clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer following radiation failure. The trial results indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity following a single intra-prostatic treatment.

 

July 9, 2007

Neuromed Appoints Dr. William L. Hunter as Chairman of the Board of Directors

VANCOUVER, BC and CONSHOHOCKEN, PA – July 9, 2007 – Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced today that Dr. William L. Hunter has been appointed Chairman of Neuromed’s Board of Directors. Dr. Hunter is co-founder and President and CEO of Angiotech Pharmaceuticals, Inc. and has served as a Director on Neuromed’s Board since 2004. “Dr. Hunter’s expertise in successfully commercializing multiple products and building Angiotech from the ground up to a global company with 1,700 employees will be very valuable to Neuromed as we enter a pivotal stage in our development,” said Dr. Christopher Gallen, President & CEO of Neuromed. “Neuromed is developing three valuable pain programs including a Phase 3 extended release formulation of hydromorphone, a first-in-class oral N-type calcium channel blocker and T-type calcium channel blockers. Retaining the best talent, including attracting accomplished board members like Dr. Hunter, will help to ensure that we are able to exploit the full potential of our programs.”

 

July 6, 2007

Medical drug research and development supported by Canada’s New Government

Vancouver, British Columbia, July 6, 2007- Researchers working in universities and hospitals across British Columbia are geting a boost from the Centre for Drug Research and Development (CDRD) thanks to $300,000 in funding from Canada’s New Government through Western Economic Diversification Canada.

 

July 3, 2007

A Global Perspective on the Impact of UBC Technologies

At the UILO we are currently developing a strategy to provide global access to appropriate UBC technologies, and we are now in the process of getting stakeholder feedback on our draft proposal.

 

July 2, 2007

BioTalent Canada Announces Partnership with Culpepper Compensation Surveys

Ottawa, ON, July 7, 2007- BioTalent Canada is partnering with Culpepper Compensation Surveys to publish a new compensation survey for the Canadian bio-economy. The Culpepper/BioTalent Canadian Bio-Economy Compensation Surveys, published by Culpepper, are designed for bioscience and life science organizations that research, develop, manufacture, and commercialize products and services for the Canadian bio-economy, delivering relevant, industry specific compensation data.

 

June 27, 2007

Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis

VICTORIA, Canada/BASEL, Switzerland, June 27, 2007 -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV – News; TSX: ASV – News) and Roche today released preliminary results for a clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.

 

June 27, 2007

BioPartnering Europe (BPE) Calls for Applications to Present

LONDON–June 27, 2007-Technology Vision Group LLC (TVG) calls for applications to present at the 15th Annual BioPartnering Europe conference (BPE), to be held in London, England on October 7-9, 2007. With nearly 90 company presentations already confirmed, do not miss your final opportunity to apply to showcase your company’s technology and products at Europe’s leading partnering conference.

 

June 20, 2007

Genome BC Welcomes New Communications Officer

VANCOUVER, B.C. – June 20, 2007- Julia White has joined Genome British Columbia as Communications Officer. She brings extensive communications and event management experience to the position. She joins the organization from The University of British Columbia where she has been for more than five years, lately as Events and Marketing Manager in the Office of Community Affairs.

 

June 19, 2007

Local Company Uncovers Underwear to Defeat Cancers Below the Waist!

Clad in undies and smiles, employees from CANTEST Clinical Research of Vancouver will join throngs of dedicated men and women in their unmentionables in Vancouver on July 7, 2007 for the BC Cancer Foundation’s Underwear Affair, a 10K run / 5K walk dedicated to finding a cure, and raising awareness, for cancers below the waist.

 

June 19, 2007

Neuromed President & CEO Dr. Christopher Gallen Named “100 Most Inspiring People in the Life Sciences Industry”

VANCOUVER, BC and CONSHOHOCKEN, PA – June 19, 2007 – Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, is pleased to announce its President & CEO, Dr. Christopher Gallen has been recognized as one of the “100 Most Inspiring People in the Life Sciences Industry” as voted by readers of PharmaVOICE magazine. Dr. Gallen will be featured, along with other recipients, in the July/August issue of PharmaVOICE magazine.

 

June 18, 2007

BD Biosciences and StemCell Technologies Launch Advanced Culture Environment for Human Embryonic Stem Cell (hESC) Research

Cairns, Australia (June 18, 2007) — BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc., a Vancouver-based life sciences company, announced today the launch of BD Matrigel™ hESC-qualified Matrix and mTeSR™1 Maintenance Medium. Together, these products offer an optimized cell culture environment for hESC research.

 

June 14, 2007

BD Biosciences and StemCell Technologies Sign License Agreements with WARF to Commercialize Novel Culture Media and Surfaces for Human Embryonic Stem Cell Research

Franklin Lakes, NJ and Vancouver, British Columbia (June 14, 2007) — BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc., a Vancouver-based life sciences company, announced today that they have each entered into a worldwide license agreement with the Wisconsin Alumni Research Foundation (WARF). The agreements will allow BD Biosciences and StemCell Technologies to develop and commercialize novel growth media and validated tissue culture surfaces that together offer a complete cell culture environment for human embryonic stem cells (hESC). Financial details of the agreements were not disclosed.

 

June 13, 2007

BioPartnering Europe (BPE) Celebrates its 15th Anniversary

June 13, 2007- Technology Vision Group LLC (TVG) is pleased to announce that the 15th Annual BioPartnering Europe conference (BPE) will be held in London, England on October 7-9, 2007.

 

June 12, 2007

Allon granted US patent for composition of matter

VANCOUVER, BC- June 12, 2007- Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon’s patent portfolio.

 

June 12, 2007

Centre for Drug Research and Development Receives $1 Million from Michael Smith Foundation

Vancouver, BC – June 12, 2007 The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine discoveries and develop them for commercial use, is the recipient of a $1 million funding grant from the Michael Smith Foundation for Health Research (MSFHR).

 

June 11, 2007

Welichem Awarded Contribution from NRC-IRAP for Research on Novel Anticancer Compound

BURNABY, BC, June 11, 2007- Welichem Biotech Inc. (the “Company”) (TSX-V: WBI), is pleased to announce that the Company was recently provided with an increase to their original contribution agreement of up to $150,000 by the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) for research and further development of its novel anticancer drug candidate, WBI-2100.

 

June 8, 2007

UVIC’S Vancouver Island Technology Park Appoints New Manager of Business Development and Marketing

Saanich, British Columbia, June 8, 2007—Av Hundle, a recent University of Victoria business grad, is the new Manager, Business Development and Marketing at UVic’s Vancouver Island Technology Park (VITP) in Saanich.

 

June 7, 2007

Perceptronix Launches LungSign.Com: Providing Exciting Information on Innovative Technology That Brings New Hope to Those at Risk for Lung Cancer

VANCOUVER, BRITISH COLUMBIA- June 7, 2007- Perceptronix Medical Inc. (“Perceptronix”), a private biotechnology company focused on detecting cancer at early stages, is pleased to announce the launch of its new website,www.lungsign.comLungSign.com is designed to be a primary resource for patients and healthcare providers interested in the early detection of lung cancer.

 

June 6, 2007

Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis

VICTORIA, June 6, 2007- Aspreva Pharmaceuticals Corporation (NASDAQ:ASPV; TSX: ASV) today announced that the U.S. Food and Drug Administration(FDA) has granted Fast Track designation for CellCept (mycophenolate mofetil,MMF) for the treatment of lupus nephritis. Aspreva is currently evaluatingCellCept for the treatment of lupus nephritis in a global phase III study.

 

June 6, 2007

MSFHR & FRSQ launch Interprovincial Directory of Researchers

Montreal and Vancouver, June 6, 2007 – A new Canadian online research resource was launched today, thanks to a joint effort between research support agencies in Quebec and British Columbia.

 

June 4, 2007

Cardiome and Astellas Announce Positive Results from ACT 2 Trial

Vancouver, Canada and Deerfield, Illinois, USA, June 4, 2007 – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced results from their recently completed Phase 3 clinical study, called ACT 2.

 

June 4, 2007

Unique Award Program for Canadian Teachers Celebrating Biotechnology

Ottawa (June 4, 2007) – BIOTECanada and Biogen Idec offers a $10,000 award opportunity, recognizing teachers for their excellence in teaching biotechnology in the classroom.

 

June 4, 2007

Cardiome and Astellas Announce Positive Results From Act 2 Trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced results from their recently completed Phase 3 clinical study, called ACT 2. The trial evaluated the efficacy and safety of the intravenous formulation of vernakalant hydrochloride (“vernakalant (iv)”) for the treatment of patients who developed atrial fibrillation or atrial flutter between 24 hours and 7 days following coronary artery bypass graft (CABG) or valve replacement surgery. In the atrial fibrillation population, 47% of patients dosed with vernakalant (iv) experienced conversion to normal heart rhythm within 90 minutes, as compared to 14% of placebo patients, a statistically significant difference (p=0.0001).

 

June 3, 2007

Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer

VANCOUVER, BC and CARLSBAD, CA, June 3, 2007 – OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced encouraging preliminary data from a Phase I/II clinical trial of OGX-011 in first-line combination therapy for advanced non-small cell lung cancer (NSCLC).

 

June 2, 2007

Study Presented at ASCO Shows Encouraging Preliminary Results for Phase II Trial of OGX-011 in Advanced Prostate Cancer

VANCOUVER and CARLSBAD, CA, June 2, 2007 – OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced preliminary data from a Phase II clinical trial of OGX-011 in combination with docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC).

 

June 1, 2007

Cardiome To Hold Conference Call

Cardiome Pharma Corp. today announced that a teleconference call and webcast will be held on Monday, June 4, 2007 at 9:00am EDT (6:00am PDT) to discuss results from the ACT 2 Phase 3 study for vernakalant (iv). A press release will be issued prior to the call.

 

June 1, 2007

Eighth Annual PMC-Sierra Science Fair Fun Run Raises More Than $50,000 for B.C. Science Fair Students

VANCOUVER, British Columbia, June 1, 2007 -The eighth annual PMC-Sierra Science Fair Fun Run, which took place on Sunday, May 27 raised $50,000 and attracted over 1,300 runners. To date, the run has raised over $310,000 for The Dr. Michael Smith Science Fair Endowment in support of Science Fair programs across B.C. After the run, participants enjoyed free giveaways, live entertainment, face painting for children and free admission to the TELUS World of Science.

 

May 31, 2007

Cardiome to Present at Bear Stearns Conference

Cardiome Pharma Corp. today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Bear Stearns Boston Biotech Confab at 2:50pm EDT (11:50am PDT) on Thursday, June 7, 2007.

 

May 30, 2007

Cardiome Announces Filing of New Drug Submission In Canada

Vancouver, Canada, May 30, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Astellas Pharma Canada, Inc., an affiliate of its co-development partner, Astellas Pharma US, Inc., has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada seeking Canadian approval to market the intravenous formulation of vernakalant hydrochloride (vernakalant (iv)), an investigational new drug for the acute conversion of atrial fibrillation.

 

May 30, 2007

Angiotech Initiates European Trial Examining the Vascular Wrap Paclitaxel-Eluting Mesh for Dialysis Patients with End-Stage Renal Disease

Vancouver, BC, May 30, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the initiation of a European study evaluating the safety and efficacy of the Vascular Wrap paclitaxel-eluting mesh after surgical implantation with an ePTFE vascular graft in the upper extremity for hemodialysis vascular access.

 

May 29, 2007

GenoLogics will Hold Live Auction in Support of Canary Derby

Victoria, BC, Canada – May 29, 2007 – GenoLogics Life Sciences Software (GenoLogics) today announced the Company will hold a live public auction on June 5, 2007 between 4:00 – 5:00pm, at the Vancouver Island Technology Park, to raise funds for the Canary Derby, a technology community soapbox race and fundraising drive to raise money for early detection cancer research through the BC Cancer Foundation.

 

May 29, 2007

Angiotech initiates European trial examining the Vascular Wrap(TM) paclitaxel-eluting mesh for Dialysis Patients with End-Stage Renal Disease

VANCOUVER, May 29, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the initiation of a European study evaluating the safety and efficacy of the Vascular Wrap(TM) paclitaxel-eluting mesh (“Vascular Wrap(TM)”) after surgical implantation with an ePTFE vascular graft in the upper extremity for hemodialysis vascular (AV) access.

 

May 28, 2007

Salmon conservation, cell research net new funding

Vancouver, BC- May 28, 2007- A pair of Simon Fraser University researchers poised to make breakthroughs in their fields will get more than anticipated in research funding from the Natural Sciences and Engineering Research Council (NSERC).

 

May 28, 2007

GenoLogics Takes Home HR Excellence of the Year Award

Victoria, BC, Canada – May 28, 2007 – GenoLogics Life Sciences Software (GenoLogics) today announced the Company was recognized by the Vancouver Island Technology Community as an excellent place to work with an outstanding HR team. Last week, GenoLogics was the proud recipient of the Human Resources Excellence Award, at the VIATeC 2007 Technology Awards Dinner. In the current competitive hiring environment, a company’s culture and HR philosophy are crucial to attracting and retaining talented people. GenoLogics has developed a unique HR strategy with the goal of being recognized as one the best places to work in Canada.

 

May 25, 2007

Centre for Drug and Research and Development Receives Additional $8 Million in Funding From the Province of BC

Vancouver, BC – May 25, 2007 The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine their discoveries and develop them for commercial use, received an additional $8 million in funding for its core facility. This investment matches the $8 million Canada Foundation for Innovation (CFI) grant CDRD received last November. It also comes on the heels of a $25 million funding grant from the Province of BC announced last month by Premier Gordon Campbell at the 2007 British Columbia Life Sciences Awards.

 

May 24, 2007

Aspreva completes expanded patient enrollment in phase III clinical trial for CellCept in pemphigus vulgaris

VICTORIA, British Columbia -May 24, 2007- Aspreva Pharmaceuticals Corporation today announced successful completion of patient enrollment in their global phase III clinical trial designed to assess the safety and efficacy of CellCept (mycophenolate mofetil) in association with corticosteroids to achieve remission in patients with active pemphigus vulgaris.

 

May 23, 2007

Reducolâ„¢ Product Range Expanded with Cholesterol-Lowering Rye Bread ~Kesko Launch Creates New Opportunities in European Functional Food Market~

Vancouver, British Columbia, May 23, 2007 – Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announces Kesko Food Ltd (Kesko) of Finland has launched a cholesterol-lowering Rye Bread with Forbes Medi-Tech’s ingredient, Reducolâ„¢. The product launch further demonstrates Forbes’ ability to move quickly into new product markets and allows the Company to target other producers and retailers in Europe selling Rye Bread. The Rye Bread will be marketed under the ‘Pirkka’ premium private label brand name.

 

May 17, 2007

Angiotech receives European approval for Quill(R) SRS wound closure product- New Class of Wound Closure Product Expected to Launch in Europe Mid-Year

VANCOUVER, May 17, 2007 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill(R) Self-Retaining System (SRS). Launched early in the year in the United States, Quill(R) SRS is expected to launch commercially in Europe mid-year.

 

May 17, 2007

BIOTECanada Supports the New Science and Technology Strategy, Mobilizing Science and Tech to Canada’s Advantage

OTTAWA, May 17, 2007- The national biotechnology industry association in Canada welcomed Canada’s new national science and technology strategy announced today by Prime Minister Stephen Harper.

 

May 15, 2007

10th Anniversary of Biotech 101 reflects “new” life sciences industry

May 15, 2007 – Vancouver “Biotechnology”, “genomes”, and “genetic engineering” are just a few of the terms that are heard more and more frequently in everyday news media, business dealings, and discussions, but what do these terms really mean? Luckily you do not need a doctorate to understand these and dozens of other new life science terms – you need just two days to take the Biotech 101 workshop offered by Life Sciences BC and BCIT.

 

May 15, 2007

Forbes Medi-Tech Reports Financial Results for the Quarter ended March 31, 2007 ~Revenue Up 122% Over Last Year~

Vancouver, Canada, May 15, 2007  – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) reports its financial results for the three months ended March 31, 2007. Comparative period for these statements is the three months ended March 31, 2006. All amounts are in Canadian Dollars unless otherwise noted.

 

May 11, 2007

Dr. Anthony Tolcher Joins Chemokine’s Clinical Advisory Board

VANCOUVER, BRITISH COLUMBIA- May 5, 2007– Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics), has joined its oncology Clinical Advisory Board. Comprised of leading oncologists and translational researchers, Chemokine’s advisory boards play an important role in guiding and participating in Chemokine’s clinical development programs.

 

May 10, 2007

Cardiome to Release First Quarter Results

Cardiome Pharma Corp. today announced that it will report 2007 first quarter financial results on the morning of Friday, May 11, 2007. Cardiome will hold a teleconference call and webcast at 10:00am EDT (7:00am PDT) on that day to discuss the results.

 

May 10, 2007

Angiotech to Market Vascular Wrap/ePTFE Graft Combination Product Through its own European Sales and Distribution Networks

Vancouver, BC, May 10, 2007-Angiotech Pharmaceuticals (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation, regarding the distribution of Angiotech’s Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product.

 

May 8, 2007

Forbes Medi-Tech Announces Pharmavite Contract Renewal ~Key Reducolâ„¢ Customer Continues Contract and Continues to Expand Product Line with Reducolâ„¢-Based Products~

Vancouver, British Columbia, May 8, 2007- Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced it has extended its supply and licensing contract with Pharmavite LLC until mid 2008 for the continued sale of Reducolâ„¢, the branded cholesterol lowering ingredient in one of Pharmavite’s leading line of dietary supplements, Nature Made ® CholestOff ® and recently launched CholestOff ® Complete.

 

May 8, 2007

Canadian and U.S. Biotechnology Companies Forging New Partnerships at the 2007 BIO International Convention- 80 Canadian companies gather at conference; establish new relationships with U.S.-based biotech firms

BOSTON, May 7 /PRNewswire/ — As 80 Canadian biotech companies cross the border into New England this week for the 2007 BIO International Convention, increased business and investment bonds between the two trading partners will be highlighted by a series of partnering events, and business and technology announcements.

 

May 7, 2007

Ondine Announces Clinical Advisory Board Member is Recipient of the 2007 IADR Periodontal Disease Research Award

VANCOUVER, May 7, 2007- Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) announces that Dr. Richard Darveau, a member of its Clinical Advisory Board, is the recipient of the 2007 Basic Research in Periodontal Disease Award from the International Association for Dental Research (IADR).

 

May 7, 2007

Pacgen announces positive results from Phase I/II trial of novel anti-fungal drug

VANCOUVER, May 7, 2007- Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) is pleased to report that topline results from its Phase I/II study of PAC-113, a novel antifungal, show it is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. Based on these results the Company plans to initiate a Phase IIb study to optimize PAC-113 dose and formulation.

 

May 3, 2007

Chemokine Therapeutics Annouces Results of Preclinical Study Conducted by M. D. Anderson Cancer Center on Its Anticancer Drug CTCE-9908

VANCOUVER, BRITISH COLUMBIA — (MARKET WIRE) — May 03, 2007 — Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the results of a study conducted by The University of Texas M. D. Anderson Cancer Center to evaluate the ability of CTCE-9908 to inhibit the metastasis and growth of the primary tumor of a human breast cancer in preclinical models. The study concluded that treatment with the Company’s CXCR4 antagonist, CTCE-9908, significantly reduced metastases and primary tumor growth in preclinical models of breast cancer. The effects of anti-metastasis could be due to inhibition of tumor cell homing; however, inhibition of primary tumor growth may indicate involvement of other mechanisms.

 

May 3, 2007

Key Patents Issued for ARCADâ„¢ Instillate for the Prevention of Surgical Adhesions

Vancouver, British Columbia, May 3, 2007 – The University of British Columbia (UBC) and ARC Pharmaceuticals Inc. (ARC) today announced that key patents relating to ARC’s lead product candidate, ARCADâ„¢ Instillate, for the prevention and treatment of surgical adhesions, were recently issued or granted in several territories. The patents are assigned to UBC and ARC previously in-licensed these technologies through an exclusive worldwide license agreement with UBC.

 

April 30, 2007

Cardiome Announces In-Licensing Agreement With Eli Lilly and Company

Vancouver, Canada, April 30, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has signed an exclusive in-licensing agreement with Eli Lilly and Company (“Lilly”) for LY458202 (“GED-aPC”), a clinical-stage drug candidate, whereby Cardiome has been granted exclusive worldwide rights to GED-aPC for all indications.

 

April 27, 2007

B.C. Launches Labour Strategy to Meet Skills Shortages

VANCOUVER, April 27. 2007 – Economic Development Minister Colin Hansen was joined by several well-known British Columbians today to launch WorkBC, an innovative new labour market strategy to ensure the Province’s success in meeting key economic priorities and advancing B.C.’s global economic competitiveness.

 

April 24, 2007

Allon Therapeutics Confirms Oral Bioavailability of AL-309

VANCOUVER, April 24, 2007— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today released new data confirming that the Company’s product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.

 

April 19, 2007

From The Lab Bench To The Bedside: Guiding Researchers Across The Valley of Death Green Light for the Centre for Drug Research and Development

Vancouver, BC – April 19, 2007- The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine their discoveries and develop them for commercial use, is the recipient of a $25 million funding grant from the Province of British Columbia. Premier Gordon Campbell made the announcement at the 2007 British Columbia Biotech Awards last night.

 

April 17, 2007

Inex Pharmaceuticals Provides Progress Update on Alnylam Collaboration

VANCOUVER, BC, April 17, 2007  – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) reported that one of its collaboration partners, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced today that it will advance a systemically delivered RNA interference (RNAi) therapeutic, ALN-VSP01, for the treatment of liver cancer and potentially other solid tumors. The announcement was made at the American Association for Cancer Research (AACR) Annual Meeting being held in Los Angeles, California. The complete details of Alnylam’s announcement can be accessed from Alnylam’s website at www.anlylam.com.

 

April 17, 2007

OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting

VANCOUVER, April 17, 2007- OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada – Clinical Trials Group at the American Association for Cancer Research 2007 Annual Meeting in Los Angeles, Calif.

 

April 16, 2007

California Superior Court Grants Preliminary Injunction Prohibiting Sirna From Using Protiva Technology

Vancouver, BC, April 16th, 2007- Protiva Biotherapeutics Inc. today reported that the California Superior Court has granted Protiva a preliminary injunction prohibiting Sirna Therapeutics Inc. from using, disclosing, transferring, licensing, selling or otherwise encumbering Protiva’s trade secrets and know how, except as permitted in the target areas defined in the original Strategic Alliance Agreement (SAA) between the two companies.

 

April 10, 2007

BC Innovation Council Announces New Chief Executive Officer

Vancouver, BC, April 10, 2007- Hector MacKay-Dunn, QC, Chair, is pleased to announce that Matthew Watson has joined BC Innovation Council as Chief Executive Officer.

 

April 10, 2007

BC Records Significant Increases in Health Research, Notes Room for Growth

VANCOUVER, April 10, 2007- Thanks to six years of provincial investment, BC now ranks as Canada’s most improved jurisdiction in the competition for health research funding, with an increase in funding from all sources of $577 million between 2000 and 2005. Yet even with these gains, BC still has room to grow. The province currently attracts less than its per-population share of national funding, a shortfall most notable in the biomedical research sector.

 

April 9, 2007

Inflazyme receives Helicon’s Statement regarding Preliminary Results of IPL455,903 in Phase 2a Memory Study

VANCOUVER, B.C., CANADA, April 9, 2007  – Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that it has received a statement from Helicon Therapeutics of New York regarding the outcome of the proof of concept Phase 2a study with IPL455,903 (HT-0712) in Age Associated Memory Impairment (AAMI).

 

April 3, 2007

MSFHR Program Heralds a New Way of Doing Business in Health Research

VANCOUVER- April 3, 2007- The Michael Smith Foundation for Health Research (MSFHR) announced today the successful applicants for funding from an innovative new program designed to pave the way for sharing research resources, information and expertise across the province’s health research institutions.

 

March 28, 2007

Cardiome Reports 2006 Results

Vancouver, Canada, March 28, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the fourth quarter and year ended December 31, 2006. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). At close of business on December 31, 2006, the exchange rate was CAD$1.00=US$0.8581.

 

March 28, 2007

Protox Initiates Phase I Study of PRX302 for Benign Prostatic Hyperplasia

Vancouver, British Columbia, March 28, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today that it has initiated a Phase 1 clinical study of PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) at two Canadian sites.

 

March 28, 2007

Forbes Medi-Tech announces Financial Results for the Year ended December 31, 2006

Vancouver, Canada – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the year ended December 31, 2006 versus the year ended December 31, 2005. All amounts are in Canadian dollars unless otherwise noted. A conference call to discuss the financial statements will be held tomorrow, March 29, 2007 at 1:30pmPT /4:30pmET.

 

March 27, 2007

Cardiome To Release 2006 Results

Vancouver, Canada, March 27, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will hold a teleconference call and webcast at 10:00am EST (7:00am PST) on Wednesday, March 28, 2007 to discuss year-end and fourth-quarter 2006 financial results.

 

March 27, 2007

Cardiome Announces Appointment of Chairman

Vancouver, Canada, March 27, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that current board member and Chief Executive Officer Bob Rieder has been elected as Chairman of the Company’s Board of Directors.

 

March 27, 2007

Allon receives approval to begin a Phase II clinical trial for Schizophrenia

VANCOUVER, March 27, 2007  â€” Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that its IND (Investigational New Drug) application with the Unites States Food and Drug Administration (FDA), filed on February 20th 2007, is now active and the Company may begin human clinical trials evaluating the Company’s product AL-108 as a treatment for schizophrenia-related cognitive impairment. Allon was selected by the United States National Institute of Mental Health-funded project TURNS (Treatment Units for Research of Neurocognition in Schizophrenia) for a Phase II clinical trial.

 

March 26, 2007

Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation

VANCOUVER, British Columbia, March 26, 2007 – Inimex Pharmaceuticals Inc.’s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.

 

March 20, 2007

Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases

Vancouver, British Columbia, March 20, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox’s PRX 302. The Journal of the National Cancer Institute (“JNCI”) has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in collaboration with Protox scientists. The paper describes the Company’s compound, PRX302, which is a prostate specific antigen (PSA) activated pro-drug being developed for the treatment of prostate cancer and BPH.

 

March 20, 2007

Inex Pharmaceuticals Conference Call Advisory 2006 Year End Operating Results

VANCOUVER, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX:IEX) announced today that it will hold a conference call and webcast on Wednesday March 21, 2007 at 9:00 am PST (12:00 noon EST) to discuss 2006 year end operating results and to provide an update on developments at the Company

 

March 15, 2007

Zymeworks announces the addition of Mr. Neil Klompas CA to its Management Team

VANCOUVER, Canada, March 15 – Zymeworks Inc. announced today that Mr. Neil Klompas, CA has joined the company in the newly created position of Director, Finance and Operations.   Mr. Klompas will be responsible for overseeing Zymeworks’ financial operations and contributing to corporate development.

 

March 15, 2007

Allon to present data at Alzheimer’s-Parkinson’s conference

VANCOUVER, March 15, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today announced that Professor Illana Gozes, the Company’s Chief Scientific Officer, has been invited to speak to the 8th International Conference on Alzheimer’s and Parkinson’s Diseases in Salzburg, Austria March 18, 2007. More than 1,800 Alzheimer’s and Parkinson’s physicians and researchers from around the world will be attending the conference.

 

March 15, 2007

Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug

Vancouver, BC, Canada (March 15, 2007) – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) announced today that it has completed the recruitment of patients in its Phase I/II study of PAC-113, a novel anti-fungal drug, in immunocompromised patients. The Company is on track to report proof of efficacy results from this study early in the second quarter of 2007.

 

March 14, 2007

NSERC Officially Opens New Pacific Regional Office in Vancouver

Vancouver, B.C., March 12, 2007 – The Honourable Maxime Bernier, Minister of Industry and Suzanne Fortier, President of the Natural Sciences and Engineering Research Council of Canada (NSERC) today announced the opening of a new NSERC regional office. Based in Vancouver, NSERC-Pacific will serve British Columbia and the Yukon.

 

March 13, 2007

Pacgen Appoints Robert DuFresne as President & CEO

Vancouver, BC, Canada, March 13, 2007 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) is pleased to announce the appointment of Robert ‘Duffy’ DuFresne as President and Chief Executive Officer. Mr. DuFresne replaces Dr. David Cheng who held the position since he co-founded the company in 2004. Dr. Cheng will continue to lead scientific affairs at Pacgen as Chief Scientific Officer and also as a Director. Mr. DuFresne will also be joining the Board as a Director.

 

March 12, 2007

Cardiome Board Chairman Retires

Vancouver, Canada, March 12, 2007 – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the retirement of the Chairman of the Company’s board of directors, Dr. Mark C. Rogers, effective today. Dr. Rogers had served as Board Chairman for approximately five years, since the merger of Cardiome with Paralex, Inc. in March 2002. Dr. Rogers also has resigned as a member of the Cardiome board.

 

March 8, 2007

Protox Therapeutics to Present at BioSquare 2007

Vancouver, British Columbia, March 8, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today that President and Chief Executive Officer Dr. Fahar Merchant will be presenting at the BioSquare 2007 conference to be held at the Lyon Convention Centre in Lyon, France, March 12 to 14. Dr. Merchant’s presentation will provide an overview and update on recent developments at the company and will take place on Tuesday, March 13 at 5:15PM in the Rhône 1 room.

 

March 7, 2007

Allon product AL-108 successful in Phase Ib clinical trial

VANCOUVER, March 7, 2007 – Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the results of the completed Phase Ib clinical trial of their product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing.

 

March 5, 2007

EaglePicher Medical Power Releases World’s Smallest Implantable Medical Battery New Line of Micro Devices Are Now a Possibility

Vancouver, BC, Canada, 5 March 2007 – EaglePicher Medical Power today announced the successful qualification of the industry’s smallest implantable-grade medical battery.   The battery’s size and shape (cylindrical, 0.260” long x 0.090” diameter) enables a device so small that it can be deployed via a minimally-invasive catheter procedure rather than traditional implantation surgery.   The device is presently undergoing clinical trials in Europe.

 

March 2, 2007

Pacgen Reports Third Quarter Financial and Operating Results

Vancouver, BC, Canada (March 1, 2007) – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) today reported financial results for the third quarter ended December 31, 2006. Amounts unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles.

 

March 2, 2007

StemCell Technologies signs worldwide distribution agreement for ALDECOUNT with Aldagen

Vancouver, BC – March 2, 2007 StemCell Technologies, Inc., a Vancouver-based life sciences company, announced today that it has signed a worldwide distribution agreement with Aldagen, Inc., a Durham, NC-based regenerative medicine company, whereby StemCell will distribute Aldagen’s ALDECOUNT ® product.   StemCell Technologies is also the worldwide distributor for Aldagen’s ALDEFLUOR ® product.

 

March 1, 2007

Protox Outlines Milestones for 2007

Vancouver, British Columbia, March 1, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today the company’s key milestones for the coming year that will help position the company as a leader in targeted therapeutics for cancer and other proliferative diseases. They include the completion of a Phase I study in prostate cancer, the initiation of a Phase I study in benign prostatic hyperplasia and the initiation of a Phase IIb study in brain cancer.

 

February 26, 2007

INEX Provides Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation

Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it is working to close the spin-out of Tekmira Pharmaceuticals Corporation (“Tekmira”) on March 31, 2007 concurrent with the end of the company’s first quarter.

 

February 23, 2007

Protox Announces Stock Options Granted

Vancouver, British Columbia, February 22, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that it has granted 1,201,000 options pursuant to its previously approved stock option plan. The options were granted at an exercise price of $0.77 and will vest over three years. The Company also granted 225,000 options on February 5, 2007 at an exercise price of $0.64, some of which vest over three years and some of which will vest upon the achievement of milestones.

 

February 23, 2007

Protox Announces prx302 Data to be Presented at ASCO Sponsored Prostate Cancer Symposium

Vancouver, British Columbia, February 23, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that additional pre-clinical efficacy and safety data on PRX302, a novel pore-forming targeted toxin, will be presented this week at the Prostate Cancer Symposium, a gathering sponsored by the American Society of Clinical Oncology (ASCO).

 

February 23, 2007

Inex Pharmaceuticals Submits Petition Against Protiva Biotherapeutics

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has submitted a petition for filing in the Supreme Court of British Columbia seeking to have Protiva Biotherapeutics Inc. (“Protiva”) declared bankrupt and that a bankruptcy order be made in respect of the property of Protiva.

 

February 22, 2007

Cardiome Announces Management Appointments

Vancouver, Canada, February 22, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the following management appointments.

 

February 21, 2007

Allon files IND for approval of Schizophrenia Phase II clinical trials

VANCOUVER — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it has filed an Investigational New Drug application (IND) with the United State Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the Company’s product AL-108 as a treatment for Schizophrenia related cognitive impairment.

 

February 20, 2007

Inex Pharmaceuticals Corporation Closes Bought Deal Financing

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today the closing of the bought deal financing announced January 30, 2007. The financing was led by Sprott Securities Inc. and included Dundee Securities Corporation and Loewen Ondaatje McCutcheon Ltd. (the “underwriters”). In addition to purchasing 9,000,000 common shares at a price of $1.55 per common share, the underwriters have also exercised their over-allotment option to purchase an additional 1,350,000 common shares at the same price. In total, the underwriters have purchased an aggregate of 10,350,000 common shares of INEX at a price of $1.55 per share, for gross proceeds to INEX of $16,042,500.

 

February 20, 2007

Geneusâ„¢ from GenoLogics to be Implemented at the Hospital for Sick Children Research Institute

Victoria, BC, Canada – February 20, 2007 GenoLogics, a leading developer of lab and data management software solutions for life sciences research, today announced that The Hospital for Sick Children Research Institute has selected Geneusâ„¢ to manage their genomics workflows and assist with collaborative stem cell research across nine labs. Geneusâ„¢ is the latest lab and scientific data management product from GenoLogics. Specially designed to address genomics challenges, Geneus is a robust LIMS built on an open, configurable informatics platform that acts as the ‘central nervous system’ within a discovery lab.

 

February 15, 2007

BC Biotech Becomes LifeSciences British Columbia and Charts New Course in Growing Canada’s Bio-Economy

February 5, 2007, Vancouver, BC — BC Biotech announces today a name change to LifeSciences British Columbia. The change in name is reflective of an even broader member association and an expanded Life Sciences Industry view beyond biopharmaceuticals. The organization will now begin to extend its advocacy, public policy development and awareness-building activities to ensure all aspects of the bio-economy continues to grow in British Columbia and Canada.

 

February 15, 2007

Med Biogene Engages The Howard Group Inc. to Provide Investor and Financial Relations Services

VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has engaged The Howard Group Inc. (HG) of Calgary, Alberta, to provide investor and financial relations services to MBI.

 

February 15, 2007

Med Biogene Enters Development Phase For Genetic Screening Test for Colorectal Cancer

VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has entered the development phase for its genetic screening test for colorectal cancer (CRC).

 

February 15, 2007

Ondine Obtains Health Canada License for Peri-Implantitis Use

VANCOUVER, Feb. 15 /CNW/ – Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announces that it has received a Health Canada license for use of its Periowave(TM) Photodisinfection system in the treatment of peri-implantitis and peri-mucositis. Peri-implantitis and peri-mucositis are inflammatory reactions to dental implants caused by bacterial infections surrounding the implant.

 

February 12, 2007

Pacgen Appoints New Scientific Advisory Board Members

Vancouver, BC, Canada (February 12, 2007) – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) announces the appointment of Dr. J. Mark FitzGerald, Dr. William Nauseef, and Dr. Brian Rowe, all world renowned experts in inflammatory diseases, to its scientific advisory board (“SAB”).

 

February 12, 2007

Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development and Corporate Restructuring ~Company Eliminates Non-Core R&D Expenses and Extends Working Capital to Mid 2008~

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the next steps for its pharmaceutical development program and restructuring measures in R&D to extend the Company’s working capital and optimize the Company’s remaining capital resources. Based on the results from the recently completed US Phase II trial, the Company’s immediate pharmaceutical objective is to out-license its cholesterol-lowering drug, FM-VP4.

 

February 8, 2007

Cardiome to Hold Analyst and Investor Day

Vancouver, Canada, February 8, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will host an Analyst and Investor Day for equity analysts and institutional investors on Wednesday, February 28, 2007 in New York City.

 

February 8, 2007

Med Biogene Receives $307,000 Grant from Natioanl Research Council Canada to Develop Genetic Biomarkers for Cardiovascular Disease

VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has received a $307,000 grant from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD).

 

February 8, 2007

Inflazyme Pharmaceuticals Announces Corporate Restructuring

VANCOUVER, BRITISH COLUMBIA–(CCNMatthews – Feb. 8, 2007) – Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that it has undertaken a corporate restructuring, following its announcement on the results of the Phase 2b CAPSICS study on January 29, 2007. The results demonstrated a surprisingly large placebo response in the asthma trial which obscured any potential effects of the drug.

 

February 7, 2007

Cardiome and Astellas Announce Acceptance of NDA for Review

Vancouver, Canada and Deerfield, Illinois, USA, February 19, 2007 — Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) and its co-development partner Astellas Pharma US, Inc. today announced that the New Drug Application (NDA) for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, has been accepted for review by the U.S. Food & Drug Administration (FDA).

 

February 6, 2007

MIGENIX provides update on license-option agreement with Schering-Plough for celgosivir in Hepatitis C

VANCOUVER, BC, & San Diego, CA, Feb. 6 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, and Schering-Plough Corporation (“Schering”) have agreed that the Schering limited period of exclusivity for data review of the celgosivir Phase II results announced November 6, 2006 has not yet commenced.

 

February 6, 2007

Ondine Reports Positive Results from its Third Consecutive Trial of Periowave(TM)

VANCOUVER, Feb. 6 /CNW/ – Ondine Biopharma Corporation (TSX: OBP;AIM: OBP) today announced results of its Periowave(TM) clinical study at the University of British Columbia, in Vancouver, BC, Canada. This 40 patient trial was designed to evaluate Periowave(TM) adjunctive therapy in the well-maintained, non-smoking periodontal patient. This is the third consecutive trial of Periowave(TM) where statistically and clinically significant outcomes have been proven in the treatment of chronic adult periodontitis.

 

February 1, 2007

Med Biogene Announces Further Promising Results on the Diagnostic Value of its Lymphoma Genetic Biomarkers

VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce the results of its latest pre-clinical studies involving its Gene Expression Profiling SystemTM for diagnosing lymphoma.

 

January 30, 2007

Findings of Genome BC-funded Scientists Published by Prestigious International Journal

VANCOUVER, B.C. – Researchers at the University of British Columbia studying cholesterol degradation by bacteria have made a significant and unexpected breakthrough by discovering a potential Achilles Heel of the pathogen that causes Tuberculosis (TB). The scientific article outlining this groundbreaking research is appearing in the January 29, 2007 issue of “Proceedings of the National Academy of Sciences, USA”.

 

January 30, 2007

Inex Pharmaceuticals Corporation Announces $13,950,000 Bought Deal

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has entered into an agreement with a syndicate of underwriters led by Sprott Securities Inc. and including Dundee Securities Corporation and Loewen Ondaatje McCutcheon Limited pursuant to which the underwriters have agreed to purchase 9,000,000 common shares on a bought deal basis, at a price of $1.55 per common share for aggregate gross proceeds to INEX of $13,950,000.

 

January 30, 2007

Perceptronix Collaborates With BC Cancer Agency on Early Oral Cancer Detection Project

VANCOUVER, Jan. 30 /CNW/ – Perceptronix Medical Inc. (“Perceptronix”) today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and technology companies to develop early screening programs for oral cancer

 

January 29, 2007

Ondine Announces Over 3,000 Patients Treated with Periowave(TM)

VANCOUVER, Jan. 29 /CNW/ – ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM: OBP) (the “Company”) announces that over 3,000 patients in Canada have been treated with the Periowave(TM) photodisinfection system since its launch at the Pacific Dental Conference in March 2006.

 

January 29, 2007

QSV Biologics, Ltd. Signs cGMP Manufacturing Contract for a Therapeutic Recombinant Protein with a US Biopharmaceutical Company

CALGARY, Jan. 29 /CNW/ – QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, announced today that they signed a cGMP manufacturing contract with an undisclosed US biopharmaceutical company located in California. The recombinant therapeutic protein manufactured by QSV will be used in upcoming human clinical studies. QSV will be responsible for technology transfer and cGMP manufacture of the clinical trial material at their licensed cGMP manufacturing facility in Edmonton. Details of the agreement have not been released.

 

January 29, 2007

GenoLogics Installs Early Version of Geneus at University of Pittsburgh Genomics and Proteomics Core Laboratories

Lab Automation Show, Palm Springs, CA, January 29, 2007, GenoLogics, a leading developer of lab and data management software solutions for life sciences research, today announced that Geneus, its new solution for the genomics market, was installed at the first customer site, the University of Pittsburgh Genomics and Proteomics Core Laboratories (GPCL). GPCL currently uses GenoLogics’ Proteusâ„¢, a lab and data management solution for proteomics research.

 

January 29, 2007

Welichem Biotech Inc. Appoints Investor Relations Officer

BURNABY, BC, Jan. 29 /CNW/ – Welichem Biotech Inc. (“WBI” or the”Company”) (TSX-V: WBI) is pleased to announce the appointment of Mr. Andrew Baren as Investor Relations Manager. Mr. Baren will take over a significant part of Welichem’s corporate communications and will update the Company’s shareholders and brokers as required.

 

January 29, 2007

Inflazyme Pharmaceuticals Announces Preliminary Outcome of the Phase 2b CAPSICS Asthma Trial

VANCOUVER, BRITISH COLUMBIA–(CCNMatthews – Jan. 29, 2007) – Inflazyme Pharmaceuticals Ltd. (TSX:IZP) announced today that it has completed the Phase 2b asthma clinical study in moderate to severe patients and the data has been unblinded.

 

January 25, 2007

Inflazyme Pharmaceuticals Completes $3 Million Private Placement

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it has successfully completed its previously announced non-brokered unit offering with the issue of 17.6 million units at $0.17 per unit for gross proceeds of $3 million (CDN).

 

January 25, 2007

Forbes Medi-Tech Provides Update on Nasdaq Listing Status

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the Company received a letter from Nasdaq indicating that the bid price for its common stock has closed below the minimum of U.S. $1.00 per share for the last 30 consecutive trading days, as required for continued inclusion on The Nasdsaq Global Market by Marketplace Rule 4450(a)(5).

 

January 24, 2007

Inflazyme Pharmaceuticals Announces Private Placement

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it has entered into a private placement agreement to issue 17.6 million units at $0.17 per unit for gross proceeds of $3 million (CDN). The Company expects the placement to close within three business days.

 

January 24, 2007

BioPartnering North America Supports the 3rd Annual Student Biotechnology Network (SBN) Biotech Career Fair

BioPartnering North America is proud to support the 3rd annual SBN Biotech Career Fair & Conference, taking place on Tuesday, February 6, 2007 at the Hyatt Regency Hotel in Vancouver, BC Canada from 5:30-9:30pm.

 

January 24, 2007

Angiotech launches the Quill(R) Self-Retaining System (SRS) – establishing a new “class” of wound closure products

VANCOUVER, Jan. 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP) today announced the U.S. launch of its Quill(R) Self-Retaining System (SRS) for tissue approximation. The Quill(R) SRS is a revolutionary concept in wound closure that harnesses advanced technology for greater accuracy, faster procedures and better results. The wound closure market in the United States is valued at approximately US $1.7 billion and has not seen any significant product innovations in many years.

 

January 24, 2007

Michael J. Fox Foundation funds Allon to evaluate AL-108 for Parkinson’s disease

VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced it has received funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate the effectiveness of Allon’s lead drug AL-108 in pre-clinical models of Parkinson’s disease.

 

January 24, 2007

The Biotechnology Human Resource Council (BHRC) now BioTalent Canada

OTTAWA — January 24, 2007 – BioTalent Canada, formerly the Biotechnology Human Resource Council (BHRC), is a non-profit organization founded in 1997 to address the human resource needs of the Canadian biotechnology sector.

 

January 23, 2007

Cardiome Pharma Corp. Closes Cross-Border Public Offering of 9,200,000 Common Shares

Vancouver, Canada, January 23, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has closed its previously-announced cross-border public offering of 9,200,000 common shares (including 1,200,000 common shares issued pursuant to the exercise of the underwriters’ over-allotment option) at US$10.50 per share for gross proceeds of US$96,600,000. Net proceeds from the offering are expected to be approximately US$90 million.

 

January 22, 2007

Cardiome Pharma Corp. Announces Exercise of Over-Allotment Option

Vancouver, Canada, January 22, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the underwriters of its cross-border public offering of 8,000,000 common shares that was priced on January 18, 2007, exercised the over-allotment option in full to purchase an additional 1,200,000 common shares at a price of US$10.50 per share. Net proceeds from the offering (including the common shares to be issued pursuant to the exercise of the over-allotment option) are expected to be approximately US$90 million.

 

January 22, 2007

Ondine Announces Positive Clinical Results from its Periowave(TM) Trial of Maintenance Therapy

VANCOUVER, Jan. 22 /CNW/ – Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that the publication of three Periowave(TM) clinical trial abstracts will be presented at the combined meetings of the International Association for Dental Research (IADR) and the American Association for Dental Research (AADR) meeting in New Orleans, March 21-24, 2007. The IADR/AADR meeting is expected to attract 5000 dental researchers from around the world who are dedicated to the prevention and treatment of oral and dental diseases.

 

January 22, 2007

iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema

VANCOUVER, Jan. 22 /PRNewswire/ – iCo Therapeutics Inc. announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for iCo-007 to treat diabetic macular edema.

 

January 22, 2007

Welichem’s Anti-cancer Drug Candidate Stimulates the Immune System

BURNABY, BC, Jan. 22 /CNW/ – Welichem Biotech Inc. (“WBI” or the”Company”) (TSX-V: WBI – News), a biotechnology company developing drugs tofight autoimmune diseases and cancer, today reports additional results for itslead anti-cancer drug candidate, WBI-2100. See Press Release datedSeptember 26, 2006, reporting the Company’s NRC-IRAP support and preliminarytest results.

 

January 22, 2007

MIGENIX Announces Initiation of Rosacea Phase II Clinical Study by Partner, Cutanea Life Sciences

VANCOUVER, BC & SAN DIEGO, CA, Jan. 22 /CNW/ – MIGENIX Inc. (TSX: MGI;OTC: MGIFF) has been notified by Cutanea Life Sciences, Inc. (“Cutanea”), its development and commercialization partner for CLS001 (topical omiganan), of the initiation of a Phase II clinical study in the treatment of rosacea. This study is being conducted in the United States by Cutanea, and is expected to be completed by the end of 2007.

 

January 22, 2007

Allon confirms progress in AL-208 Phase II clinical trial

VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has progressed into the randomized portion of its Phase II human clinical trial evaluating the Company’s product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company also announced the selection of the 300 mg dose, the highest one tested, in the randomized portion of the trial.

 

January 19, 2007

Perceptronix appoints Ms. Rohini Hira, Vice President Sales and Marketing

VANCOUVER, Jan. 19 /CNW/ – Perceptronix CEO Carl Roy announced the appointment of Ms. Rohini Hira to the position of Vice President Sales and Marketing effective December 15th, 2006. Ms. Hira has the vision and experience to commercialize Perceptronix’ early cancer detection products and services in Canada, the US and the EU.

 

January 18, 2007

Forbes Medi-Tech Expands Reducolâ„¢ Sales in Portugal with the Addition of Modelo Continente to Customer List ~Reducolâ„¢-Based Products Sold Through Country’s Leading Retailers~

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the expansion of Reducolâ„¢-based products in Portugal through one of its largest food retailers, Modelo Continente. The cholesterol-lowering ingredient will be featured in a range of dairy products including a Strawberry Flavor Yogurt Drink, Original Flavor Yogurt Drink, UHT Milk and Dairy Spread. The products will be marketed under the Modelo Continente private-label brand.

 

January 18, 2007

BioPartnering North America Attracts Key Stakeholders From the International Biotech Industry

SANTA CRUZ, CALIFORNIA–(CCNMatthews – Jan. 18, 2007) – There is now less than a month to go until this year’s BioPartnering North America (BPN) which will be held in Vancouver, B.C., Canada, on February 4-6, 2007 as a partnership between Technology Vision Group LLC (TVG), BC Biotech, BioAlberta and BIOTECanada.

 

January 18, 2007

Protox Reports promising interim results from prostate cancer study

Vancouver, British Columbia, January 18, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced interim results from its ongoing Phase I clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer. The findings to date indicate that PRX302 is well tolerated and shows encouraging signs of therapeutic activity following a single intra-prostatic injection.

 

January 17, 2007

Angiotech wins patent infringement case in the Netherlands

VANCOUVER, Jan. 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced today that they received a favorable decision from a Dutch Court in a patent dispute against Conor Medsystems, Inc. (“Conor”).

 

January 17, 2007

Cardiome Pharma Corp. Announces Public Offering

Vancouver, Canada, January 17, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced today that it is offering 8,000,000 common shares in the United States and Canada pursuant to a preliminary prospectus supplement. The corporation will grant the underwriters an option to purchase up to an additional 1,200,000 common shares at the offering price during the period ending 30 days from the closing of the offering to cover over-allotments, if any.

 

January 16, 2007

UK Court of Appeal releases decision on Angiotech patent

VANCOUVER, Jan. 16 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced today that the UK Court of Appeal released its decision (Conor v. Angiotech) regarding one of Angiotech’s several patents related to paclitaxel-eluting stents.

 

January 15, 2007

Forbes Medi-Tech Expands Its Line of Reducolâ„¢ Products with Jeronimo Martins in Portugal

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that one of Portugal’s largest retail chains, Jeronimo Martins, has launched a range of dairy products incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducolâ„¢. Effective immediately, Jeronimo Martins will begin offering a Strawberry Flavor Yogurt Drink, Original Flavor Yogurt Drink & UHT Milk under the Salutare private-label brand.

 

January 15, 2007

Inex Pharmaceuticals Announces Appeal Date for Spin-out of Tekmira Pharmaceuticals

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that on February 6, 2007 the British Columbia Court of Appeal will hear Protiva Biotherapeutics, Inc. (“Protiva”) appeal of the Supreme Court of British Columbia’s ruling that approved the INEX Plan of Arrangement to transfer all of the Company’s transferable assets and liabilities to a spin-out Company, Tekmira Pharmaceuticals Corporation (“Tekmira”). The Supreme Court of British Columbia approved the Plan of Arrangement on November 24, 2006.

 

January 9, 2007

Chemokine Therapeutics acquires certain assets of Globe Laboratories Inc.

VANCOUVER, Jan. 9 /PRNewswire-FirstCall/ – Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, is pleased to announce that Chemokine Therapeutics (B.C.) Corp. (“CTBCC”), a wholly-owned subsidiary of Chemokine Therapeutics Corp. and Globe Laboratories Inc. (“Globe”), have entered into a definitive agreement wherein Globe agreed to sell certain assets (consisting mainly of laboratory equipment and leasehold improvements) to CTBCC for consideration of CD$375,935 based on the fair market value of these assets as determined by an independent appraisal, and to cease all future research and development services by Globe to the Company.

 

January 9, 2007

Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations

CAMBRIDGE, Mass., and VANCOUVER, BC, January 9, 2007 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Inex Pharmaceuticals Corporation (TSX: IEX) announced today that Alnylam has taken a worldwide exclusive license to Inex’s liposomal delivery formulation technology for the discovery, development, and commercialization of RNAi therapeutics, and that the companies have expanded their technology research and manufacturing alliance on lipid-based delivery technology. In addition, Inex will receive three InterfeRxâ„¢ license options, subject to Alnylam review and third-party obligations, to develop its own RNAi therapeutic products. Inex will also receive exclusive access to Alnylam’s intellectual property to develop oligonucleotide drugs that act through an immune stimulation mechanism, outside the RNAi pathway.

 

January 9, 2007

Inflazyme Pharmaceuticals Ltd., to Appear On MN1.com

VANCOUVER, British Columbia, Jan. 9, 2007 (PRIME NEWSWIRE) — Dr. Kevin Mullane, President and CEO of Inflazyme Pharmaceuticals Ltd. (Other OTC:IZYPF) (TSX:IZP), will be featured live on Market News First (www.mn1.com) for an exclusive interview with the MN1 news team. The interview is scheduled for January 11, 2007, at 11 a.m. CST. Dr. Mullane will provide an overview of the company, a summary of the corporate goals as well as its future value drivers in the stock market.

 

January 9, 2007

Aspreva to Release 2006 Fourth Quarter and Full Year Results on February 7th

VICTORIA, BC, Jan. 9 /CNW/ – Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, announced today that the company will release financial and business results for the fourth quarter and full year ending December 31, 2006 on Wednesday, February 7th. The Company will hold a conference call and webcast beginning at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these results.

 

January 8, 2007

Allon drug selected for clinical trial in the treatment of cognitive impairment in schizophrenia

VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that its drug AL-108 will be investigated in a Phase II human clinical trial as a potential treatment for cognitive impairment in schizophrenia. The United States National Institute of Mental Health-funded project, Treatment Units for Research of Neurocognition in Schizophrenia (TURNS) selected Allon’s drug AL-108 and will conduct the Phase II clinical trial.

 

January 8, 2007

Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics

Cambridge, UK and Vancouver, BC, Canada – Cambridge Antibody Technology (CAT) and iCo Therapeutics Inc. announce today that CAT has granted iCo an exclusive worldwide licence for the development and commercialisation of CAT-213, a human monoclonal antibody previously developed by CAT as a potential treatment for allergy disorders including asthma, allergic rhinitis and allergic conjunctivitis. iCo Therapeutics plans to advance the compound initially for the treatment of ocular allergies including allergic conjunctivitis.

 

January 3, 2007

QLT USA receives final payment for generic dermatology and manufacturing business

VANCOUVER, Jan. 3 – Further to the Company’s press release dated December 22, 2006, QLT Inc. (NASDAQ: QLTI – News; TSX: QLT – News) announced today that its wholly-owned subsidiary, QLT USA, Inc., has received, in advance of its due date of the end of the first quarter of 2007, the remaining 40% of the purchase price from the sale of QLT USA’s generic dermatology and manufacturing business to Tolmar Inc., a private pharmaceutical company.